Alnylam Collaborator Regeneron Reports Positive First-in-Human Results for CIDEBsiRNA

Type 2 Diabetes Clinical Trial and Competitive Landscape Analysis: 200+ Key Companies Shaping the Future of Type 2 Diabetes Therapeutics Space | DelveInsight

DelveInsight released a comprehensive report on the Type 2 Diabetes competitive landscape, analyzing 200+ pipeline drugs from 170+ active players. The report highlights recent approvals including Eli Lilly's FOUNDAYO (orforglipron) and Novo Nordisk's once-weekly insulin options, alongside promising pipeline therapies targeting various mechanisms of action. Key developments include positive Phase III results for CagriSema, elecoglipron, and other novel GLP-1 receptor agonists, with approximately 60+ drugs in late-stage development.

Alnylam And Regeneron Says Data Published In The The New England Journal Of Medicine, Reports Up To 80% Reduction In Liver Fat Sustained For 36 Weeks After Single CIDEBsiRNA Dose In MASLD Patients

Citigroup Adjusts Alnylam Pharmaceuticals Price Target

Citigroup has revised its price target for Alnylam Pharmaceuticals, Inc., lowering it from $320 to $250.

Alnylam Reports Positive Five-Year HELIOS-B Data for Amvuttra

Five-year study results indicate that continuous treatment with Amvuttra significantly reduces the risk of death and cardiovascular events in patients with ATTR cardiomyopathy.

Alnylam-Licensed Elebsiran Shows Positive Results in Phase 3 ECLIPSE 1 Trial for Hepatitis Delta

Topline results from the Phase 3 ECLIPSE 1 trial demonstrate that the combination of elebsiran, an siRNA licensed from Alnylam, and tobevibart achieved significant virologic response in patients with hepatitis delta.

8-K filing — ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Filed: 2026-11-05 AccNo: 0001178670-26-000080 Size: 152 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events